Crossmark

Adoptive transfer of tumor-infiltrating lymphocytes in melanoma: a viable treatment option

Crossref DOI link: https://doi.org/10.1186/s40425-018-0391-1

Published Online: 2018-10-03

Published Print: 2018-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Rohaan, Maartje W. https://orcid.org/0000-0003-1470-9427
van den Berg, Joost H.

Kvistborg, Pia

Haanen, John B. A. G.
License Information

Text and Data Mining valid from 2018-10-03
More Information

Article History

Received: 11 April 2018

Accepted: 25 July 2018

First Online: 3 October 2018

Ethics approval and consent to participate

: Not applicable.

: Not applicable.

: MR declares to have no competing interests. JB has received grants from NEON therapeutics, BMS and Medimmune. PK has received compensation for advisory roles from NEON therapeutics and Personalis and has received grants from Merck and BMS. Through JH, NKI has received compensation for advisory roles from BMS, Merck, Roche, NEON therapeutics, Pfizer and Ipsen and NKI has received grants from BMS, Merck, Novartis and NEON therapeutics.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.